EOLS Q2 2022 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q2 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$37M+42.4% YoY

Gross Profit

$21M57.4% margin

Operating Income

-$21M-57.4% margin

Net Income

-$23M-63.2% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+9.6%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$211M

Total Liabilities

$164M

Stockholders' Equity

$47M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$26M	+42.4%
Gross Profit	$21M	$15M	+44.3%
Operating Income	-$21M	-$15M	-39.6%
Net Income	-$23M	-$16M	-50.4%

Revenue Segments

Product

$37M100%